0.00Open0.05Pre Close0 Volume0 Open Interest1.00Strike Price0.00Turnover5483.11%IV52.20%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier-5DDays to Expiry0.05Time Value100Contract SizeAmericanOptions Type0.3054Delta1.1065Gamma13.80Leverage Ratio-2.4583Theta0.0000Rho4.21Eff Leverage0.0000Vega
Biora Therapeutics Stock Discussion
NEWS
Biora Therapeutics Announces Completion of Multiple-Ascending Dose (MAD) Cohorts for Clinical Trial of BT-600
Benzinga· 2 mins ago
Dow Jones· 1 min ago
Results demonstrated targeted drug delivery and absorption in the colon, with 3-4 times lower drug levels in blood
Remainder of BT-600 clinical trial progressing well and on schedule
No comment yet